InvestorsHub Logo
Followers 30
Posts 4098
Boards Moderated 0
Alias Born 07/25/2007

Re: None

Wednesday, 05/03/2023 12:11:57 PM

Wednesday, May 03, 2023 12:11:57 PM

Post# of 1106

One key data point from the trial was that Elahere's objective response rate (ORR) was 42.3% with 12 complete responses, compared to a 15.9% ORR with no complete responses for study participants who had platinum-based chemotherapy.



That is pretty impressive to me, especially since the data was derived from send or third line patients.

https://www.fool.com/investing/2023/05/03/why-immunogen-stock-is-soaring-wednesday/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IMGN News